The unknown biology of the unknown primary tumour: a literature review.
暂无分享,去创建一个
[1] Manuel Molina,et al. Unknown primary , 2004, Journal of surgical oncology.
[2] C. la Vecchia,et al. Epidemiology of unknown primary tumours. , 2002, European journal of cancer.
[3] J. Hainsworth,et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Coebergh,et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. , 2002, European journal of cancer.
[5] F. Kokocinski,et al. Automated Screening for Genomic Imbalances using Matrix-Based Comparative Genomic Hybridization , 2002, Laboratory Investigation.
[6] P. Jallepalli,et al. Chromosome segregation and cancer: cutting through the mystery , 2001, Nature Reviews Cancer.
[7] C. Klein,et al. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. , 2001, Seminars in cancer biology.
[8] J. Hainsworth,et al. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. , 2001, Cancer journal.
[9] J. Hainsworth,et al. Gemcitabine in the Second-Line Therapy of Patients with Carcinoma of Unknown Primary Site: A Phase II Trial of the Minnie Pearl Cancer Research Network , 2001, Cancer investigation.
[10] B. Trock,et al. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance , 2000, British Journal of Cancer.
[11] James D. Evans,et al. K‐ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4A, p21WAF‐1, cyclin D1, erbB‐2 and erbB‐3 in resected pancreatic ductal adenocarcinoma , 2000, International journal of cancer.
[12] C. Rinker-Schaeffer,et al. Metastasis-suppressor genes: a review and perspective on an emerging field. , 2000, Journal of the National Cancer Institute.
[13] Karen H. Vousden,et al. The ins and outs of p53 , 2000, Nature Cell Biology.
[14] J. Hainsworth,et al. Management of patients with cancer of unknown primary site. , 2000, Oncology.
[15] T. Liehr,et al. Patterns of genomic imbalances in human solid tumors (Review). , 2000, International journal of oncology.
[16] J. Hainsworth,et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] J. Hainsworth,et al. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Friberg,et al. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). , 1999, European journal of cancer.
[19] J. Arends,et al. Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer. , 1998, Anticancer research.
[20] A. Horwich,et al. Establishing Germ Cell Origin of Undifferentiated Tumors by Identifying Gain of 12p Material Using Comparative Genomic Hybridization Analysis of Paraffin‐Embedded Samples , 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[21] W. Kuo,et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.
[22] S. Knuutila,et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. , 1998, The American journal of pathology.
[23] N. Pavlidis,et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. , 1998, Anticancer research.
[24] J. Roodenburg,et al. Detection of unknown occult primary tumors using positron emission tomography , 1998, Cancer.
[25] Y. Nishiwaki,et al. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer. , 1998, Oncology reports.
[26] T. Shankey,et al. Common patterns of genetic evolution in human solid tumors. , 1997, Cytometry.
[27] B Johansson,et al. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. , 1997, Cancer research.
[28] J. Hainsworth,et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Arends,et al. Microvessel density in unknown primary tumors , 1997, International journal of cancer.
[30] C. Croce,et al. Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.
[31] S. Fox,et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.
[32] B. Iacopetta,et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. , 1996, Human pathology.
[33] A. Harris,et al. EARLY EXPRESSION OF bcl‐2 PROTEIN IN THE ADENOMA–CARCINOMA SEQUENCE OF COLORECTAL NEOPLASIA , 1996, The Journal of pathology.
[34] A. Sandberg,et al. Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. , 1996, The Journal of urology.
[35] B. Lembersky,et al. Metastases of unknown primary site. , 1996, The Medical clinics of North America.
[36] N. Pavlidis,et al. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. , 1995, Anticancer research.
[37] K. Bland,et al. Oncogene Protein Co‐Expression Value of Ha-ras, c-myc, c-fos, and p53 as Prognostic Discriminants for Breast Carcinoma , 1995, Annals of surgery.
[38] R. Motzer,et al. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] K. Hess,et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] G. Daugaard. Unknown primary tumours. , 1994, Cancer treatment reviews.
[41] H. Kim,et al. Expression of cellular oncogenes in human gastric carcinoma: c‐myc, c–erb B2′ and c‐Ha‐ras , 1993, Journal of surgical oncology.
[42] A. Harris,et al. bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.
[43] R. Lenzi,et al. The biology of unknown primary tumors. , 1993, Seminars in oncology.
[44] R. Motzer,et al. Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. , 1993, Seminars in oncology.
[45] I. Ellis,et al. Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. , 1993, BMJ.
[46] J. Abbruzzese,et al. p53 gene mutation spectrum in human unknown primary tumors. , 1993, Anticancer research.
[47] A. Szporn,et al. ras and c-myc protein expression in colorectal carcinoma , 1992, Diseases of the colon and rectum.
[48] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[49] E. Dmitrovsky,et al. Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. , 1991, Journal of the National Cancer Institute.
[50] J. Daly,et al. Flow cytometry and prognostic implications in patients with solid tumors. , 1990, Surgery, gynecology & obstetrics.
[51] D. Niedzwiecki,et al. Metastatic Adenocarcinomas of Unknown Primary Site: Prognostic Variables and Treatment Results , 1990, American journal of clinical oncology.
[52] C. Bell,et al. Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. , 1989, Cancer research.
[53] T. Chevalier,et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. , 1988, Archives of internal medicine.
[54] M. Tattersall,et al. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. , 1987, European journal of cancer & clinical oncology.
[55] N. B. Atkin. Chromosome 1 aberrations in cancer. , 1986, Cancer genetics and cytogenetics.
[56] E. Cadman,et al. An analysis of 1539 patients with cancer of unknown primary site , 1986, Cancer.
[57] E. Casper,et al. Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin. , 1985, Cancer treatment reports.
[58] D. Hedley,et al. Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. , 1985, European journal of cancer & clinical oncology.
[59] B. Barlogie,et al. Flow cytometry in clinical cancer research. , 1983, Cancer research.
[60] G. Bodey,et al. Sequential chemotherapy for adenocarcinoma of unknown primary , 1983, American journal of clinical oncology.
[61] S. Balcerzak,et al. Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study. , 1983, Cancer treatment reports.
[62] P. Sheedy,et al. Computed tomography in search of cancer of unknown origin. , 1982, JAMA.
[63] E. Levine,et al. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. , 1982, Radiology.
[64] M. Markman. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965--1979. , 1982, Medical and pediatric oncology.
[65] M. Tattersall,et al. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. , 1980, The New England journal of medicine.
[66] M. Tattersall,et al. Unknown primary adenocarcinoma: incidence of overinvestigation and natural history. , 1979, British medical journal.
[67] R. M. Wolf,et al. Metastatic and histologic presentations in unknown primary cancer. , 1977, Seminars in oncology.
[68] J. Yuhas,et al. Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. , 1974, Cancer research.
[69] R. Hahn,et al. Treatment of the patient with adenocarcinoma of unknown origin , 1972, Cancer.
[70] Norman Goldstein,et al. Metastases in carcinoma. Analysis of 1000 autopsied cases , 1950, Cancer.